Clinical Scorecard: Enhancing Patient Outcomes with Bispecific Antibodies Targeting BCMA: Focus on Infection Risks

At a Glance

Key Highlights

• Anti-BCMA bispecific antibodies (e.g., teclistamab, elranatamab) show high infection rates including severe and fatal infections compared to CAR T-cell therapies.
• Hypogammaglobulinemia is frequent with anti-BCMA therapies and contributes to increased susceptibility to bacterial, viral, and opportunistic infections.
• Strategies such as intravenous immunoglobulin (IVIG) prophylaxis and dosing interval optimization reduce infection risk and improve patient outcomes.

Guideline-Based Recommendations

Diagnosis

• Monitor immunoglobulin G (IgG) levels regularly to detect hypogammaglobulinemia (IgG <400 mg/dL).
• Assess for signs of bacterial, viral, and opportunistic infections including Pneumocystis jirovecii and cytomegalovirus.

Management

• Administer IVIG as primary prophylaxis when IgG levels fall below 400 mg/dL to reduce serious infections.
• Consider spacing dosing intervals of bispecific antibodies (e.g., from weekly to every two weeks) after achieving partial or complete response to reduce infection risk.
• Evaluate fixed duration therapy approaches to allow recovery of humoral immunity.

Monitoring & Follow-up

• Close monitoring for infections especially grade ≥3 infections during and after anti-BCMA bispecific antibody therapy.
• Monitor timing of infections, noting higher early infection risk post CAR T-cell therapy and ongoing risk with bispecific antibodies.
• Track response status to guide dosing interval adjustments.

Risks

• Increased risk of severe and fatal infections with anti-BCMA bispecific antibodies compared to CAR T-cell and antibody drug conjugate therapies.
• Persistent hypogammaglobulinemia leading to vulnerability to bacterial, viral, and opportunistic infections.
• Higher infection risk with continuous bispecific antibody treatment versus one-time CAR T-cell therapy.

Patient & Prescribing Data

Patients with multiple myeloma treated with anti-BCMA therapies including bispecific antibodies, CAR T-cells, and antibody drug conjugates.

Bispecific antibodies are associated with higher rates of severe infections and hypogammaglobulinemia; IVIG prophylaxis and dosing interval modifications significantly reduce infection incidence and improve safety.

Clinical Best Practices

• Implement routine IgG monitoring and initiate IVIG prophylaxis promptly when IgG <400 mg/dL.
• Adjust bispecific antibody dosing intervals based on patient response to minimize infection risk while maintaining efficacy.
• Educate patients on infection signs and maintain vigilant infection surveillance throughout treatment.
• Consider fixed duration therapy trials to balance treatment efficacy and immune recovery.

References

• MajesTEC-1 trial (teclistamab infection data)
• MagnetisMM-3 trial (elranatamab infection data)
• CARTITUDE-1 trial (cilta-cel infection data)
• Nath et al. retrospective analysis of infection risks
• Amsterdam University Medical Center IVIG prophylaxis study
• Mount Sinai IVIG retrospective study
• FDA approval for teclistamab dosing interval extension
• Consensus recommendations on IVIG prophylaxis
• Older guidelines on immune globulin replacement
• LimiTEC study evaluating fixed duration teclistamab therapy